The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

Modern lifestyles, frequent prescription updates, and continuous lens enhancements drive Japan's spectacle lens market, promoting specialized designs ...

Jefferies analyst Glen Santangelo downgraded Bausch Health (BHC) to Hold from Buy with a price target of $8, down from $12, after the company ...

Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday, sending its U.S.-listed shares ...

(Reuters) -Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday. In December, the ...

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers ...

More than just a functional accessory, sunglasses are a powerful fashion statement capable of elevating any outfit. In 2025, this sentiment is truer than ever, as high-end labels like Prada, Miu Miu, ...

It provides range of vision beyond one focal point. Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release. Using intermediate ...

The collaboration may expand into other ocular conditions. Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age ...

The content is produced solely by The Conversation. Sunglasses, or dark glasses, have always guarded against strong sunlight, but is there more to “shades” than we think? The pupils of our ...

In the US, enVista Aspire is the first Low-Cyl toric IOL below 1.5D at the IOL plane, enhancing treatment options. Bausch + Lomb announced the commercial launch of its enVista Aspire monofocal and ...